Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
As biosimilars enter the market, comparisons of product quality are needed. Manufacturing differences may lead to differences in critical quality attributes, which affect efficacy. Therefore, critical quality attributes (structure and biological activity) of Remicade® and of 2 biosimilar products (Flixabi®/Renflexis® and Remsima®/Inflectra®) were determined. We assessed binding to tumor necrosis factor in a fluorescence competitive binding assay; potency in a luciferase reporter gene assay; percentages of galactosylated glycan, afucose plus high mannosylated glycans, and charged glycan; FcγRIIIa (CD16) binding (assessed by 3 methods); and antibody-dependent cell-mediated cytotoxicity (ADCC) in the NK92-CD16a cell line and in peripheral blood mononuclear cells (PBMC). The results of Fab-related activity were similar for all products. Compared with Remicade®, Flixabi® had a lower percentage of charged glycan, and Remsima® had a higher percentage of galactosylated glycan and a lower percentage of afucose plus high mannosylated glycans. Whereas Remsima® and Remicade® are expressed in a Sp2/0 cell line, Flixabi® is expressed in a CHO cell line. Despite this difference, galactosylated glycans from the 3 products were not correlated with the expression system. The results of all 3 methods used in this study indicated that FcγRIIIa binding was lower with Remsima® than with Remicade®. The percentage of ADCC in NK92-CD16a cells was lower with Remsima® and higher with Flixabi® compared with Remicade®, but was similar for all 3 products in PBMC. Surface expression of CD16 was 5.7-fold greater on NK92-CD16a cells than on PBMC. Combined percentages of afucosylated and high mannosylated glycans were positively correlated with FcγRIIIa binding and ADCC in NK92-CD16 cells, while no correlation was observed in PBMC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Case studies for biosimilars like Enbrel® (an IgG1-based fusion protein) and Remicade® (a mAb) demonstrated batch-to-batch differences exceeding ten percentage points in glycoform composition and total sugar content, yet without detectable effects on clinical performance.79,80”
From Impact of process parameters on IgG glycosylation in CHO systems: a comprehensive quantitative analysis (2026) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that typical PP adjustments are unlikely to impact biological efficacy meaningfully.”
From Impact of process parameters on IgG glycosylation in CHO systems: a comprehensive quantitative analysis (2026) · cites this paper as [79]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The process-induced glycan variations we reported here fall within or below these ranges”
From Impact of process parameters on IgG glycosylation in CHO systems: a comprehensive quantitative analysis (2026) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shields, R. L., Lai, J., Keck, R., O'Connell, L. Y., Hong, K., Meng, Y. G., Weikert, S. H. A., & Presta, L. G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202069200 · Cited by 1,835
Terminal sugars of Fc glycans influence antibody effector functions of IgGs
Raju, T. S. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.007 · Cited by 521
Fc glycans of therapeutic antibodies as critical quality attributes
Reusch, D., & Tejada, M. L. (2015) · Glycobiology · doi:10.1093/glycob/cwv065 · Cited by 404
Scallon, B. J., Tam, S. H., McCarthy, S. G., Cai, A. N., & Raju, T. S. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2006.09.005 · Cited by 396
Physicochemical characterization of Remsima®
Jung, S. K., Lee, K. H., Jeon, J. W., Lee, J. W., Kwon, B. O., Kim, Y. J., Bae, J. S., Kim, D.-I., Lee, S. Y., & Chang, S. J. (2014) · mAbs · doi:10.4161/mabs.32221 · Cited by 330
Self-citationHatjiharissi, E., Xu, L., Santos, D. D., Hunter, Z. R., Ciccarelli, B. T., Verselis, S., Modica, M., Cao, Y., Manning, R. J., Leleu, X., et al. (2007) · Blood · doi:10.1182/blood-2007-01-070656 · Cited by 282
Niwa, R., Natsume, A., Uehara, A., Wakitani, M., Iida, S., Uchida, K., Satoh, M., & Shitara, K. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.08.009 · Cited by 244
Niwa, R., Sakurada, M., Kobayashi, Y., Uehara, A., Matsushima, K., Ueda, R., Nakamura, K., & Shitara, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2263 · Cited by 187
Zhou, Q., Shankara, S., Roy, A., Qiu, H., Estes, S., McVie‐Wylie, A., Culm‐Merdek, K., Park, A., Pan, C., & Edmunds, T. (2008) · Biotechnology and Bioengineering · doi:10.1002/bit.21598 · Cited by 184
The choice of mammalian cell host and possibilities for glycosylation engineering
Butler, M., & Spearman, M. (2014) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2014.06.010 · Cited by 175 · cited 1×
“, CHO cells or mouse myeloma cells).(12,13) Our data also showed such variation, as Flixabi (produced using CHO cells) and Remicade (produced using SP2/0 cells) had similar percentages of galactosylated glycans.”
Background
Research works printed but not linked: 2
- Janssen Biotech REMICADE® (infliximab). Titusville, NJ: Janssen Immunology; 2016 12 [accessed 2017 3 8]. http://www.remicade.com
- Bergelson S Biological methods for assessment of Fc effector function of antibodies and Fc-containing molecules [oral presentation]. Presented at: Biopharmaceuticals Emerging Best Practices Association's Fifth Annual Biological Assay Conference; 2012 September 27; Lisbon,Portugal [accessed 2017 3 8]. http://www.bebpa.org/wp-content/uploads/2012/11/Svetlana-Bergelson-BEBPA-2012-final.pdf
Cited by
Duivelshof, B. L., Jiskoot, W., Beck, A., Veuthey, J., Guillarme, D., & D’Atri, V. (2019) · Analytica Chimica Acta · doi:10.1016/j.aca.2019.08.044 · Cited by 106
Lee, J., Kang, H. A., Bae, J. S., Kim, K. D., Lee, K. H., Lim, K. J., Choo, M. J., & Chang, S.-J. (2018) · mAbs · doi:10.1080/19420862.2018.1440170 · Cited by 60
Self-citationAdalimumab Biosimilars in Europe: An Overview of the Clinical Evidence
Bellinvia, S., Cummings, F. J. R., Ardern‐Jones, M. R., & Edwards, C. J. (2019) · BioDrugs · doi:10.1007/s40259-019-00355-4 · Cited by 53
On the glycosylation aspects of biosimilarity
Hajba, L., Szekrényes, Á., Borza, B., & Guttman, A. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.009 · Cited by 48
Peng, J., Patil, S. M., Keire, D. A., & Chen, K. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b02637 · Cited by 43
Metadata
- Authors
- Lee, C., Jeong, M., Lee, J. J., Seo, S., Cho, S. C., Zhang, W., & Jaquez, O.
- Affiliations
- Samsung Bioepis (South Korea) (KR)
- Biogen (United States) (US)
- Biogen (Switzerland) (CH)
- Corresponding author
- Lee, Changsoo
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2017-06-22
- Volume
- 9
- Issue
- 6
- Pages
- 968-977
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- PMC
- PMC5540080
- OpenAlex
- W2653070086
- Cited by
- 57
- References
- 16
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 9 · 2020: 9 · 2019: 14 · 2018: 11
- FWCI
- 4.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- mAbs (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Samsung
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
- Keywords
- infliximab, biosimilars, Remsima, glycosylation, critical quality attributes, FcγRIIIa binding, antibody-dependent cellular cytotoxicity, natural killer cells, CHO cell expression, TNF-alpha inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®. https://app.cochat.ai/papers/10.1080/19420862.2017.1337620
- The paper
- Lee, C., Jeong, M., Lee, J. J., Seo, S., Cho, S. C., Zhang, W., & Jaquez, O. (2017). Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®. mAbs. https://doi.org/10.1080/19420862.2017.1337620
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.